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Genesetenrichmentanalysis(GSEA)associatesgenesetsandphenotypes,itsuseispredicatedonthechoice
ofapre-definedcollectionofsets.ThedefactostandardimplementationofGSEAprovidessevencollections
yet there are no guidelines for the choice of collections and the impact of such choice, if any, is unknown.
Herewecompareeachofthestandardgenesetcollectionsinthecontextofalargedatasetofdrugresponsein
human cancer cell lines. We defineand test a newcollection based on geneco-expressionin cancer cell lines
to compare the performance of the standard collections to an externally derived cell line based collection.
The results show that GSEA findings vary significantly depending on the collection chosen for analysis.
Henceforth, collections should be carefully selected and reported in studies that leverage GSEA.
W
ith the advent of high-throughput gene expression profiling using microarrays and RNA sequencing,
researchers are now able to quantify the expression of a cell’s genes in response to various environ-
ments, stimuli or other controlled experimental factors
1. It has thus become common practice to refer
to a cell’s expression profile, meaning the complete set of its gene expression levels for a specific experimental
condition. Among numerous applications of gene expression profiling, the identification and quantification of
differential gene expression have been shown to be informative and reproducible across different teams and
technology platforms
2,36.
Differential expression of individual genes have led to critical discoveries in numerous diseases such as the
genes ESR1, ERBB2 and AURKA used in breast cancer molecular subtyping
3. However it is now well established
that it is generally not individual genes but sets of genes (and sets of gene products) that collectively define
phenotypes such as targeted cancer therapy response. This suggests that the association of a set of expression
levelswithphenotypemaybemorerobustthanbiomarkersconsistingofindividualgeneexpressionlevels.Tothis
end Gene Set Enrichment Analysis (GSEA) has been developed to associate gene sets with sample phenotypes
4,5.
In the context of cancer therapy decision-making, it is important to understand the mechanism of action of
anticancer agents and to identify efficient drug response biomarkers. However given the rapid development of
many new compounds, it is neither sustainable nor ethical to test all of them in clinical trials
6. Therefore several
research groups investigated the use of large panels of cell lines to effectively screen the therapeutic potential of
numerous compounds
7–9. In particular Garnett and colleagues at the Welcome Trust Sanger Institute recently
publishedtheresultsofalargepanelof727uniquecancercelllinesscreenedwith138drugs(theresultingdataset
is referred to hereafter as the Cancer Genome Project’s dataset or CGP).
Developingtherapeuticstrategiesbasedonsuchstudiesisanelusiveandattractivetarget.Muchofthedifficulty
in establishing reliable predictors lies in the genetic diversity of human cancers and so gene set association is a
natural investigative avenue. Cell line drug response trials offer a vast array of quantifiable phenotypes and so
GSEA can be utilized to find gene sets associated with a particular drug response
10,11.
GSEArequiresapre-definedcollectionofgenesetsasinputthenprovidesascoretoeachgeneset’sassociation
withaphenotype.WerefertothedistributionofthesescoresattributedtoaparticularcollectionbyGSEAasthat
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SCIENTIFIC REPORTS | 4 : 4092 | DOI: 10.1038/srep04092 1collection’s enrichment profile. In this work we hypothesize that
different gene set collections yield heterogeneous enrichment pro-
files when investigating the biological mechanisms of drug response
in cell lines. We therefore tested the use of various collections within
GSEA and compared their enrichment profiles within the context of
drug response in human cancer cell lines. We analyzed the CGP
pharmacogenomic dataset to compare the associations of gene
expression with drug response over 138 drugs administered to a
panel of 727 cancer cell lines.
Of these standard collections, C2 provides asignificant number of
highlyenrichedgenesetsaswellasthenethighestscoringgenesetfor
many drugs. C2 is a collection composed of sets extracted mainly
frombiomedicalliteratureandbiologicaldatabasessuchastheKyoto
Encyclopedia of Genes and Genomes
12 (KEGG) or Reactome
13.I ti s
followed in both these categories by C4: a collection of gene sets
created by data mining cancer-related microarray data. All other
collections perform significantly poorer. We further observe that
there is little overlap between the standard collections and that col-
lectionperformanceispredictedbygenecountorsharedphenotypic
characteristics with the phenotype under study. Lastly we showed
that a new collection based on co-expressed gene sets extracted from
cancer cell lines experiments supplants C2 as the lead collection of
gene sets when included in the analysis.
Results
ToinvestigatetheimpactofaparticularcollectiononGSEA’sresults,
weconductedgenesetanalysesfor138drugstestedon727celllines
8.
The collections tested were the seven standard collections made
available through the tool’s distributor, together these seven collec-
tions are refered to as the Molecular Signatures Database (MSigDB).
There exists no de facto consensus among the community as to
whichgenesetcollectionsaretobeusedwithinGSEA. Ofthefirst32
hits on a PubMed search for GSEA, 9 articles did not specify the
source of their gene sets, 7 articles noted a manual curation and
omitted the methodology, 14 specified specific particular instances
or subsets of the collections within MSigDB and only 1 article spe-
cified that the entire MSigDB was used (supplementary file 1).
Justifications for the choices made were almost uniformly omitted.
The seven collections are generated using different strategies and
thus the number of unique genes accounted for within a collection
varies. Table 3 shows the number of unique genes contained in each
collection.
We compared the number of gene sets in each of the MSigDB
collections (Figure 1A, Table 1). With a total of 8761 unique gene
Table 3 | Number of unique gene sets and unique genes per col-
lection used in gene set enrichment analyses
Gene set collection # unique gene sets # unique genes
HGSK 1335 12153
C1 287 30012
C2 3761 21050
C3 770 14085
C4 799 10062
C5 1046 8278
C6 188 11250
C7 1910 19841
Table 1 | Collections available from the Broad Institute
Label Descriptive title Description
C1 positional gene sets Collection of sets grouped by physical location on chromosome and cytogenetic bands.
C2 curated gene sets CollectionofsetscollectedfromheterogenicsourcesbutwithafocusonthepathwaydatabasesBioCarta
(http://www.biocarta.com),KEGG(http://www.genome.jp/kegg),Pathwayinteractiondatabase(
http://pid.nci.nih.gov), Reactome (http://www.reactome.org), SigmaAldrich (http://www.
sigmaaldrich.com/life-science.html), Signaling gateway (http://www.signaling-gateway.org),
signal transduction KE (http://stke.sciencemag.org), SuperArray (http://www.superarray.com),
manuallycuratedgenesetsfromtheMYCTargetGeneDatabase(http://www.myccancergene.org/
site/mycTargetDB.asp) It also includes some sets identified by a mammalian microarray study
31.
C3 motif gene sets Collection of sets of genes themed around regulatory motifs pulled from an individual study, ie.
thosediscovered by the motif identified by Xie et al.
32 from the TRANSFAC database
33.
C4 computational gene sets Collection of gene sets created by data mining cancer-related microarray data in three studies
14,34,35.
C5 GO gene sets Curated sets derived by gene ontology
22.
C6 oncogenic signatures Sets derivedfromNCBIGEOsusingan unspecifiedmethodology andunpublished experimentsrelating
to perturbation of cancer genes in unspecified ways.
C7 immunologic signatures Manual curation of gene sets originating in unspecified human and mouse immunology studies
generated by the Human Immunology Project (http://www.immuneprofiling.org)
Table 2 | WilcoxonRankSumtestofhighscoringgenesets(NES.
2.0) by collection accross drugs
Set 1 Set 2
p-value of Wilcoxon Rank Sum
test (double sided hypothesis)
HGSK c1 1.24E-33
HGSK c2 0.21
HGSK c3 2.89E-39
HGSK c4 2.78E-06
HGSK c5 4.61E-29
HGSK c6 5.23E-31
HGSK c7 2.45E-23
c1 c2 1.91E-28
c1 c3 6.67E-05
c1 c4 3.97E-18
c1 c5 0.56
c1 c6 0.38
c1 c7 0.016
c2 c3 8.26E-35
c2 c4 7.8E-04
c2 c5 1.20E-23
c2 c6 1.03E-25
c2 c7 8.06E-19
c3 c4 1.75E-25
c3 c5 6.85E-08
c3 c6 5.29E-06
c3 c7 1.60E-08
c4 c5 2.05E-13
c4 c6 1.60E-15
c4 c7 5.49E-10
c5 c6 0.32
c5 c7 0.48
c6 c7 0.1
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4092 | DOI: 10.1038/srep04092 2sets, the number of gene sets contained in each of the seven collec-
tions ranges from 188 (C6) to 3761 (C2). To assess the overlap
between these collections we adapted the H index, which is com-
monly used to estimate a researcher’s scientific productivity
18,i n
order to quantify the overlap between two collections of gene sets
(see Methods). We used this new overlap index, referred to as the g
index, to compute the overlap between each possible pair of gene set
collections.Figure1Brepresentstheresultinggindicesasaheatmap.
These indices range in value between 0.0106 and 0.0223 (mean 5
0.0167, sd 5 0.00352.) All scores are available in supplementary file
2. We observed that the highest degree of overlapping is observed
between C2, a collection of gene sets curated from biological data-
bases and biomedical literature (Table 1) and C4, a collection com-
posed of gene sets created by mining three large microarray studies
(Table1)with gindexof 0.0223, doubling themaximal overlap score
of C1. The C4 and the Gene Ontology set C5 share the next highest
overlapping index (g index of 0.0212). C1, based on gene position in
cytogeneticbands,showsverylittleoverlapwithallsets(maximumg
index of 0.0118 with the C2 set.) C1 is the only collection based on
gene proximity while all other collections attempt to group genes
basedonphenotypes, pathways orwithin theclassification proposed
by Gene Ontology
22.
We refer to the distribution of enrichment scores attributed to a
collection by GSEA as that collection’s enrichment profile. For each
drug we performed a gene set enrichment analysis with each indi-
vidual collection to produce 138 enrichment profiles for each collec-
tion. Under the assumption that highly enriched gene sets are more
indicative of a collection’s value than the overall distribution of its
sets,wecomparedthedistributionsofnormalizedenrichmentscores
with absolute values greater than 2 for each collection (Figure 2A).
Withinthe overall density graphweobserved an approximately nor-
mal distribution with a mean absolute normalized enrichment score
(NES) of around 1.0 for all collections. At the high end of the density
curves we note that the C4 collection contains the highest scoring
gene sets overall, followed by C2 and C6 (Figure 2A). We also
counted the number of enriched gene sets for each drug within each
collection (Figure 2B). Overall, GSEA identified significantly more
enriched gene sets in the C2 and C4 collections (Table 2).
In order to understand the relative effectiveness of each collection
inprovidinghighlyenrichedgenesetsinthegivencontextweplotted
the fractional contribution of the top scoring sets for the aggregation
ofalldrugs.Eachdrug waspolledforitstopscoringgeneset(highest
absolute NES) and the set’s collection of origin was identified. The
ratio of sets contributed by a collection to the total of these top
scoring sets is that collection’s fractional contribution. The number
ofgenesetspolledperdrugwasincrementedfromonetofiftyandthe
results are plotted in Figure 3. This procedure permits a competitive
analysis of the gene set collections. We observed that the C2 collec-
tion is the dominant collection followed by C4 and the remaining
collections do remarkably less well with little distinction among
them.
We introduced a new, data-driven collection to the competitive
analysis in order to compare the leading MSigDB collections to an
external collection. We also sought to test whether the standard
collections offered the highest scoring gene sets for the phenotype
understudy.Thiscollectionwasbuiltbycomputingsetsoftightlyco-
expressed genes in cancer cell lines produced by GlaxoSmithKline
and published by Greshock et al.
20. We performed a hierarchical
clustering analysis to compute the nested structure of co-expression
gene sets (Figure 4, see Methods). We repeated the competitive ana-
lysis described previously with this new collection of co-expressed
gene sets, referred to as HGSK (short for hierarchical
GlaxoSmithKline.) As can be seen in Figure 3B the HGSK collection
dominates the remainder of the collections mostly at the expense of
the C2collection. However, when agreaternumber of enriched gene
sets are considered (n . 30), C2 contributed more and more gene
sets and approached HGSK’s contribution. The C4 collection’s con-
tribution remains largely unaffected by the inclusion of HGSK. The
contributions of other collections remain negligible.
Discussion
Despite the widespread use of gene set enrichment analyses in bio-
medical research, the choice of the gene set collection is rarely dis-
cussed and its impact on the overall analysis results remains an open
question. Here we examine the varied expression profiles yielded by
the standard collections when performing gene set enrichment ana-
lyses within the specific context of drug response in cancer cell lines.
We do this by contrasting the performance of the seven standard
collections curated by the Broad Institute. Among these standard
collectionsthereisaremarkablevarianceinthenumberandstrength
of association shown in the results. Notably C2 and C4 aggregate
significantly more gene sets associated with the phenotypes under
Figure 1 | (A)Number andidentity ofgenesets identified ashighlyenriched(absolutenormalized enrichment score .2.0,maximumFDR,25%across
all drugs). (B) Heatmap of gene collection overlap score (g-index).
www.nature.com/scientificreports
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studies may enjoy a positive bias as to gene set association to pheno-
type given that the phenotypes under study is drug response in
cancer cell lines. However a collection creation strategy based on
cancer studies is clearly not a predictor of performance on our met-
rics as is demonstrated by the poor performance of the oncogenic
signature collection C6.
To further explore the impact of gene set collection on the GSEA
results, we built our own collection, referred to as HGSK, based on
hierarchical clustering analysis of co-expressed genes in an inde-
pendent dataset of cancer cell lines. We then compared the results
offered by this collection to simulate an unfiltered data-driven
approach to the study of drug response in cancer cell lines.
Unsurprisingly, the HGSK collection outperforms the leader among
Figure 2 | (A)Densityplotrepresentingthedistributionofnormalizedenrichementscoresforalldrugsineachcollectionindividually.(B)Heatmapofthe
number of highly enriched gene sets (absolute normalized enrichement score . 2.0, FDR , 25%) for each drug, in each collection. Gene set
collections are listed along the bottom of the figure and drugs along the right. Darker hues of blue indicate a greater number of enriched gene sets for a
particular drug.
Figure 3 | (A) Fractional contribution of each collection to the set of top scoring gene sets with n gene sets per drug. n is plotted along the abscise. The
ordinanceshowsthefractionoftopgenesetscontributedbyeachcollectiontothesetoftopscoringgenesets.Asnincreases,ahighernumberofgenesets
per drug are assumed to be relevant or significant. Collection C2 is the highest contributor by a large margin, followed by C4, all other collections
contributetoanegligibledegree.ThefractionalcontributionofC4peaksbefore10topgenesetsperdrug,coincidingwithC2’slow.Thereisaslighttrend
downward in C4’s contribution afterwards and a lesser trend upwards in the case of C2. (B) Fractional contribution of all Broad’s collections plus our
data-driven gene set collection, referred to as HGSK.
www.nature.com/scientificreports
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lysis HGSK gains come at the expense of C2 (curated primarily from
pathway databases) and not C4 (which shares an oncological pedi-
gree with HGSK.) This suggests that the signal provided by the
unsupervised clustering algorithm tended towards the identification
of genes co-expressed in pathways and not communalities between
cancer cultures. However despite its better performance, enriched
HGSK gene sets do not lend themselves to immediate biological
interpretation, as they are not labeled using prior knowledge.
Nonetheless this might be alleviated to a certain degree with third
party annotation tools such as the Gene Ontology, which could be
used to annotate most HGSK gene sets although not all of them.
A set of results that illustrates the interpretation and association
tradeoff particularly well is found within the EGFR/ERBB2-target-
tingdrugs:Erlotinib,Gefitinib,LapatinibandBIBW2992.TheHGSK
co-expression based gene set HGSK-547 is attributed a NES over 2.0
in three of these four drugs. STRING-DB
23 (Search Tool for the
Retrieval of Interacting Genes/Proteins Database) finds the gene
set to be significantly enriched in protein-protein interactions (p ,
1E-16) and to be enriched in the KEGG pathway Tight Junction (p-
value 5 4E-5). However little else is known about this set a priori
with the exception of the co-expression of itsmembers. On the other
hand the standard collections often provide sets that reference lit-
erature relevant to the nature and origin of the gene collection. A C2
set JAEGER_METASTASIS_DN is another highly enriched gene set
for EGFR targeting drugs, its title is suggestive of biological implica-
tions and their source. This second set consists of genes found to be
down-regulatedinmetastasesofmelanomainastudygearedtowards
identifying differential expression signatures between primary melano-
mas and melanoma metastases
24. Note that in this case, the gene set is
not associated by protein or pathway interactions instead they are
revealed by a former study. A second interesting note here is that in
this case the C2 set: JAEGER_METASTASIS_DN held a higher aggreg-
ate score among a family of drugs (EGFR) than the synthetic HGSK set
whereas the co-expression based collection usually provides between
60% to 40% of top scoring gene sets as can be seen from Figure 2.
Results from C2 and HGSK collections concur that chemosensi-
tivity to EGFR/ERBB2 inhibitors is associated with the upregulation
of cellular tight junction proteins among including the Claudin
familyofgenes(Claudin-3,4,7).Theseproteinsassistinmaintaining
cell polarity and in the recruitment of other signaling proteins and
therefore were hypothesized to be involved in tumoregenesis
25.
Recent work has shown that Claudin-7 inhibits cell migration of
human non-small cell lung cancer cells NCI-H1299 via an ERK/
MAPK dependent process
26. According to Lu and co-workers, the
overexpression of Claudin-7 diminished the phosphorylation of
ERK1/2 and hence inhibited the aggressiveness of lung cancer
through a MAPK/ERK dependent pathway. EGFR is an upstream
activator of this pathway and thus it may be that the upregulation of
these tight junction protein genes may attenuate cancer invasiveness
in the presence of EGFR inhibitors
26. Our results suggest that this
family of proteins would be an interesting target of further research
to elucidate their potential as prognostic biomarkers for patient res-
ponse to EGFR inhibitors. A recent study showed that Claudin-7
sensitizes lung cancer cells to Cisplatin treatment through a caspase
dependent pathway
27.
IntheCGPstudy, Garnettetal.identifiedERBB2expressionasan
indicatorofLapatinibresponse
8.Thisissupportedbythepresenceof
the ERBB2 gene symbol in the top scoring gene set for Lapatinib
sensitivity: COLDREN_GEFITINIB_RESISTANCE_DN. This gene
set is constructed based on microarray gene expression profiling of
Gefitinib testing on non-small cell lung cancer cell lines
28.
The results of the GSEA analyses for the MEK1/2 inhibitors were
investigated. Selumetinib and PD0325901 are investigational drugs
that inhibit the MEK 1 and 2 dual-specificity kinases that upregulate
the RAS/RAF/MEK/ERK pathway in MEK-overexpressing tumors.
PathwaysassociatedwithsensitivitytoMEKinhibitorswerefoundto
be enriched in genes involved in the innate immune response. For
example, a pattern of genes from the Toll-like receptors pathway
(TLR2, TLR8, CD86, CD14) is known to activate immune cell res-
ponses. Recently a work by Peroval et al, 2013 emphasized the com-
plex role of MAPK signaling pathways in the transcriptional
regulation of Toll-like receptors
29. It is possible that these receptors
would trigger cell death when MEK kinases are degraded.
Thus while GSEA offers interesting results and is valuable in the
generation of hypotheses for further investigation, the utility of the
standard collections, in the context of drug response in cancer cell
lines, varies. In this context, C2 contributes 2 high scoring sets for
each submitted by C4. Of further interest is the particularly poor
performance of the C5 set which is based on the Gene Ontologies
collection and the C6 collection based on oncogenic signatures. The
C6collectionwasexpectedtodowellgiventhenatureofthecelllines.
Both of these fare far worse than a collection based on data mining
immunology research. As expected, the HGSK co-expression based
gene set collections scores high. This further demonstrates the sens-
itivityoftheGSEAprocess tothecollectionusedintheanalyses.The
HGSK collection also highlights the value offered by the annotation
of the standard, curated collections. It is important to note that
HGSK itself is built from a dataset that closely resembles the dataset
being probed. This is done to model a data-driven approach to gene
set collection creation, no claims are made about it being a useful
collection outside of this context. Our intent here is to show the
variation in the results among the collections currently being used
by the community. Furthermore only the MSigDB gene set collec-
Figure 4 | CreationoftheHGSKsetcollectionisdonebycreatingagene-
gene distance measure based on the reciprocal of a gene-gene
correlation matrix from the expression of tumour cell lines in the GSK
dataset.Genes areclustered usingtraditional hierarchicalclusteringbased
on the distance measure. Depth first recursive tree generation is done,
iterating over the prior sub-trees of cluster. Sets containing less than 15
genes or more than 500 are discarded.
www.nature.com/scientificreports
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tumour cell lines. In addition, despite its popularity, the gene set
analysis method as proposed faces some criticism
30.
In conclusion, gene-set association with cancer drug response
done by GSEA are sensitive to the gene-set collection used and two
gene set collections consistently offer results of a higher significance
in the context of drug response in cancer cell lines. Research lever-
aging GSEA should closely evaluate gene set collection selection
criteria. Studies published using the tool should precisely report
the nature of the collection used in the analyses.
Methods
The overall analysis design is represented in Figure 5 and the details of each step are
described here.
Gene set analysis. The gene set enrichment analysis (GSEA) technique developed by
Subramanian and colleagues
14 is a widely used method of measuring the association
between a set of genes and a phenotype in gene expression profiling data sets. GSEA
enablesdetectionofgenesetsenrichedingenesthataresignificantlyassociatedwitha
phenotype ofinterest. Suchenrichmentis computed using the Kolmogorov-Smirnov
(KS) statistic
15. This statistic compares the anticipated random distribution of a set’s
genes and their actual distribution among a genome-wide list of genes ranked based
on their association with the phenotype. The KS statistic is then normalized for gene
set size and its significance is adjusted to take into account multiple hypotheses
testing. A Java implementation of this method
16 is made publicly available by the
authors. GSEA requires an a priori gene set collection to be defined. Therefore,
alongside the tool, the Broad Institute makes available several gene set collections,
referred to as MSigDB
17, which is described in the next section.
Gene set collections. Seven collections of gene sets are made available for use with
GSEA bythe BroadInstitute. (http://www.broadinstitute.org/gsea/msigdb/index.jsp)
Thesecollections,alltogether,arereferred toasMSigDB
17.Wedownloadedthe latest
version(4.0)ofthecollectionsfromtheaboveURL.Table1givesabriefdescriptionof
each collection, summarizing the information available from the website.
Overlap between gene set collections. In order to measure the overlap between
collectionsofgenesetseachpairofcollectionswassubjectedtoapairwisecomparison
of gene sets based on the h-index
18 and the Jaccard index
19 in which the ratio of the
cardinality of the intersection of the sets to the cardinality of the union of the sets is
calculated. This index, referred to as g9, is calculated using the following formula:
g0~ Ci\Cj
   
Ci|Cj
   
For collections C and D that provide sets C1 through Cm and D1 through Dn
respectively, g(C,D) is the largest proportion of the n3m pairings where g9 is greater
toorequaltog.Wereferredtothismetricasthegenesetoverlapindexortheg-score.
Co-expression gene set collection based on cancer cell line data. In addition to the
Broad’s collections of gene sets, we created a new collection based on a fully data-
driven analysis of cancer cell lines. This collection of sets was built using gene co-
expressiondatafromanindependentdatasetof311cancercelllines,referredtoasthe
Figure 5 | Overallanalysisdesignusedinourcomparativestudy.Firstwecalculatedtheoverlapbetweeneachpairofgenesetcollections.Secondweused
a large pharmacogenomic dataset (CGP) to rank all the genes with respect to their association to response to each of the 138 drugs. Third we
usedtheserankingstogetherwiththegenesetcollectionstorunmultipleGSEA.Fourththeresultsareaggregatedtocomparethemostenrichedgenesets
across collections. The results are then interpreted by taking into account the overlap between collections.
www.nature.com/scientificreports
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20. A gene-expression correlation matrix was calculated
and a distance matrix was taken as 1 minus the correlation matrix. We then
used the resulting distancematrix to generate a hierarchical clustering
21 of the cancer
cell lines’ genes. The clustering was recursively partitioned into all possible sets
that respected the hierarchy and were composed of at least 15 and no more than 500
genes in size. Figure 4 summarizes the creation of the HGSK collection. The
resulting co-expression gene sets are provided in Supplementary File 4.
Generankingbasedonassociationwithdrugresponse.Tocomputeagenome-wide
ranking of genes based on their associations with drug sensitivity, we used the area
under the dose response curve (AUC) as a measure of drug sensitivity
8 and we
assessed the association between gene expression and drug response using a linear
regression model controlled for tissue type. For each gene i we fit two linear models,
M0 and M1:
M0 : Y~b0zbtT
M1 : Y~b
0
0zb
0
iGizb
0
tT
whereYdenotesthedrugsensitivityvariable(AUC),GandTdenotetheexpressionof
gene i and the tissue type respectively and bs are the regression coefficients, i.e., b90 is
theintercept,b9tistheregressioncoefficientforthecategoricalvariableTrepresenting
the tissue type and b9i: regression coefficient for the continuous variable G
representing the expression of the gene of interest. The strength of gene-drug
association is quantified by b9i, above and beyond the relationship between drug
sensitivityandtissuetype.ThevariablesYandGarescaled(standarddeviationequals
to 1) in order to get standardized coefficients from the linear model. Significance of
the gene-drug association is estimated by computing the F statistic using the analysis
of variance (ANOVA) comparing the two nested models, M0 and M1. All genes are
then ranked with respect to their F statistic, that is the significance of the association
between their expression and drug sensitivity, and the direction of the corresponding
association (negative if expression of gene i is association with drug resistance,
positive otherwise).
Gene set enrichment analysis. To assess the association of a collection of gene sets
withsensitivitytoeachofthe138drugsscreenedinCGP,weusedversion2.0.13ofthe
GSEA tool developed by the Broad Institute. Pre-ranked GSEA requires two input
files: a gene set collection (the Broad’s collections for instance) and a genome-wide
ranking of genes, as described previously. We ran pre-ranked GSEA on each gene set
collection tocomputeenrichmentscoresfor each gene set within the collections. The
magnitude of normalized enrichment scores and FDR values were used to evaluate
the effectiveness of each collection in identifying candidate gene sets that influence
drug response in cancer cell lines.
1. Lockhart, D. J. et al. Expression monitoring by hybridization to high-density
oligonucleotide arrays. Nat Biotech 14, 1675–1680 (1996).
2. Shi, L. et al. The MicroArray Quality Control (MAQC) project shows inter- and
intraplatform reproducibility of gene expression measurements. Nat. Biotechnol.
24, 1151–1161 (2006).
3. Haibe-Kains, B. et al. A Three-Gene Model to Robustly Identify Breast Cancer
Molecular Subtypes. JNCI J. Natl. Cancer Inst. 104, 311–325 (2012).
4. Hung, J.-H., Yang, T.-H., Hu, Z., Weng, Z. & DeLisi, C. Gene set enrichment
analysis: performance evaluation and usage guidelines. Brief. Bioinform. 13,
281–291 (2011).
5. Maciejewski, H.Genesetanalysismethods:statisticalmodelsandmethodological
differences. Brief. Bioinform. DOI:10.1093/bib/bbt002 (2013).
6. Weinstein, J. N. Drug discovery: Cell lines battle cancer. Nature 483, 544–545
(2012).
7. Shoemaker,R.H.TheNCI60humantumourcelllineanticancerdrugscreen.Nat.
Rev. Cancer 6, 813–823 (2006).
8. Garnett, M. J. et al. Systematic identification of genomic markers of drug
sensitivity in cancer cells. Nature 483, 570–575 (2012).
9. Barretina,J.etal.TheCancerCellLineEncyclopediaenablespredictivemodelling
of anticancer drug sensitivity. Nature 483, 603–307 (2012).
10. Sherman-Baust, C. A., Becker, K. G., Wood Iii, W. H., Zhang, Y. & Morin, P. J.
Gene expression and pathway analysis of ovarian cancer cells selected for
resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res 4, 21 (2011).
11. Rusnak, D. W. et al. Assessment of epidermal growth factor receptor (EGFR,
ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib
(TykerbH, GW572016) in an expanded panel of human normal and tumour cell
lines. Cell Prolif. 40, 580–594 (2007).
12. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res. 28, 27–30 (2000).
13. Croft, D. et al. Reactome: a database of reactions, pathways and biological
processes. Nucleic Acids Res. 39, D691–D697 (2010).
14.Subramanian,A.etal.Genesetenrichmentanalysis:aknowledge-basedapproach
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A.
102, 15545–15550 (2005).
15. Sheskin, David J. in Handb. Parametr. Nonparametric Stat. Proced. 261–276
(Chapman & Hall, 2011).
16. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J. P. GSEA-P: a
desktop application for Gene Set Enrichment Analysis. Bioinformatics 23,
3251–3253 (2007).
17.Liberzon,A.etal.Molecularsignaturesdatabase(MSigDB)3.0.Bioinformatics27,
1739–1740 (2011).
18. Hirsch, J. E. An index to quantify an individual’s scientific research output. Proc.
Natl. Acad. Sci. U. S. A. 102, 16569–16572 (2005).
19. Levandowsky, M. & Winter, D. Distance between Sets. Nature 234, 34–35 (1971).
20.Greshock,J.etal.MolecularTargetClassIsPredictiveofInvitroResponseProfile.
Cancer Res. 70, 3677–3686 (2010).
21. R Core Team. R: A Language and Environment for Statistical Computing. (R
Foundation for Statistical Computing, 2013). at ,http://www.R-project.org..
22.Ashburner,M.etal.GeneOntology:toolfortheunificationofbiology.Nat.Genet.
25, 25–29 (2000).
23. Franceschini, A. et al. STRING v9.1: protein-protein interaction networks, with
increased coverage and integration. Nucleic Acids Res. 41, D808–D815 (2012).
24. Jaeger, J. et al. Gene Expression Signatures for Tumor Progression, Tumor
Subtype, and Tumor Thickness in Laser-MicrodissectedMelanoma Tissues. Clin.
Cancer Res. 13, 806–815 (2007).
25. Morin, P. J. Claudin proteins in human cancer: promising new targets for
diagnosis and therapy. Cancer Res. 65, 9603–9606 (2005).
26. Lu, Z. et al. Claudin-7 inhibits human lung cancer cell migration and invasion
through ERK/MAPK signaling pathway. Exp. Cell Res. 317, 1935–1946 (2011).
27. Hoggard, J. et al. Claudin-7 increases chemosensitivity to cisplatin through the
upregulation of caspase pathway in human NCI-H522 lung cancer cells. Cancer
Sci. 104, 611–618 (2013).
28. Coldren, C. D. Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non-
Small Cell Lung Cancer Cell Lines. Mol. Cancer Res. 4, 521–528 (2006).
29. Peroval, M. Y., Boyd, A. C., Young, J. R. & Smith, A. L. A Critical Role for MAPK
Signalling Pathways in the Transcriptional Regulation of Toll Like Receptors.
PLoS ONE 8, e51243 (2013).
30. Tripathi, S., Glazko, G. V. & Emmert-Streib, F. Ensuring the statistical soundness
of competitive gene set approaches: gene filtering and genome-scale coverage are
essential. Nucleic Acids Res. 41, e82–e82 (2013).
31. Newman, J. C. & Weiner, A. M. L2L: a simple tool for discovering the hidden
significance in microarray expression data. Genome Biol. 6, R81 (2005).
32.Xie,X.etal.Systematicdiscoveryofregulatorymotifsinhumanpromotersand39
UTRs by comparison of several mammals. Nature 434, 338–345 (2005).
33. Wingender, E. et al. TRANSFAC: an integrated system for gene expression
regulation. Nucleic Acids Res. 28, 316–319 (2000).
34.Segal,E.,Friedman,N.,Koller,D.&Regev,A.Amodulemapshowingconditional
activity of expression modules in cancer. Nat. Genet. 36, 1090–1098 (2004).
35. Brentani, H. et al. The generation and utilization of a cancer-oriented
representation of the human transcriptome by using expressed sequence tags.
Proc. Natl. Acad. Sci. 100, 13418–13423 (2003).
36. Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C, Beck, A. H., Aerts, H. J.
W. L. & Quackenbush, J. Inconsistency in large pharmacogenomic studies.
Nature, 504(7480), 389–393. doi:10.1038/nature12831 (2013).
Author contributions
A.R.B. and B.H.-K. were responsible for the design and execution of the study, collation of
study materials, the microarray analysis of study samples, the collection, assembly and
verification of thedata,dataandstatisticalanalysisand interpretationand final manuscript
writing; N.E.-H. assisted with the collation of study materials, the microarray analysis of
study samples, data analysis and interpretation and final manuscript writing. A.H.B. and
H.J.W.L.A. contributed to the interpretation of the results and participated to the
manuscript writing. B.H.K. supervised the study. All authors read and approved the final
manuscript.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Bateman, A.R., El-Hachem, N., Beck, A.H., Aerts, H.J.W.L. &
Haibe-Kains, B. Importance of collection in gene set enrichment analysis of drug response
in cancer cell lines. Sci. Rep. 4, 4092; DOI:10.1038/srep04092 (2014).
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-sa/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4092 | DOI: 10.1038/srep04092 7